Metabolic Research
AOD-9604
Modified fragment of human growth hormone studied historically for metabolic hypotheses. Not an established approved obesity medicine.
Limited Human EvidenceExperimental
View peptide →
Explore peptides by research area, mechanism and evidence level.
Each profile classifies the compound, explains the proposed mechanism, and labels what is still unknown. Compare two or three entries on the compare page, filter by research category, or open sourced studies.
Metabolic Research
Modified fragment of human growth hormone studied historically for metabolic hypotheses. Not an established approved obesity medicine.
View peptide →
Tissue Research
Experimental pentadecapeptide investigated primarily in preclinical gastrointestinal and tissue-injury models. Human evidence is extremely limited.
View peptide →
Growth Hormone Research
Long-acting GHRH analog studied in healthy adults for prolonged GH and IGF-I secretion. Not an approved therapy for general use.
View peptide →
Longevity Research
Synthetic tetrapeptide associated with pineal peptide research and aging hypotheses. Human anti-aging efficacy is not established.
View peptide →
Growth Hormone Research
Ghrelin-receptor GH secretagogue used in some diagnostic and research contexts. Not established as an FDA-approved wellness therapy.
View peptide →
Growth Hormone Research
Older ghrelin-receptor GH secretagogue known experimentally to stimulate GH and, in some contexts, appetite. Not an approved medicine.
View peptide →
Growth Hormone Research
Selective ghrelin-receptor GH secretagogue characterized mainly in experimental models. Not an approved medicine.
View peptide →
Metabolic Research
Mitochondrial-derived peptide studied in cell and mouse metabolic models. Human therapeutic use is not established.
View peptide →
Neurological Research
Synthetic tuftsin-derived heptapeptide studied for anxiolytic and nootropic hypotheses, including work outside the U.S. Not FDA-approved.
View peptide →
Metabolic Research
GLP-1 receptor agonist approved in the United States for specific diabetes and weight-management indications, depending on product and labeling.
View peptide →
Neurological Research
Synthetic ACTH fragment analog studied as a nootropic/neuroprotective candidate in some countries. Not FDA-approved.
View peptide →
Growth Hormone Research
GHRH (1-29) analog that was previously marketed in the U.S. Current routine availability and approved status should not be assumed from historical branding.
View peptide →
Tissue Research
Marketed research peptide associated with thymosin beta-4 biology. Clinical effectiveness and product identity are not sufficiently established.
View peptide →
Growth Hormone Research
Growth hormone–releasing factor analog approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy — not a general weight-loss medicine.
View peptide →
Metabolic Research
Dual GIP and GLP-1 receptor agonist approved in the United States for specific diabetes and weight-related indications, depending on product labeling.
View peptide →